Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-FInding Study of Elismetrep (K-304) in the Treatment of Acute Migraine

NCT06848075 is registered in ClinicalTrials.gov with Kallyope Inc. as lead sponsor.

NCT NCT06848075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06848075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-FInding Study of Elismetrep (K-304) in the Treatment of Acute Migraine
Lead sponsor
Kallyope Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 11, 2025
Completion date
August 4, 2025
Enrollment
431 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

migraine